Alto Neuroscience expands credit facility to $75M, extends maturity to 2029

Alto Neuroscience, Inc.

Maturity extended from Dec 2026 to Jan 2029; max facility raised from $35M to $75M.
$20M funded at closing; up to $30M tranche contingent on milestones, $25M tranche subject to lender approval.
Interest: Prime +1.45% (floor 8.45%) plus 1% PIK; cash runway covenant begins Jan 2026.
Loan conversion feature: up to $9M convertible at $10.49 (first $4M) and $4.8259 (next $5M).
Warrants repriced to $3.7122; new warrant issued for additional shares expiring Jan 2035.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.